TLDR Finasteride significantly reduces prostate cancer risk.
The Prostate Cancer Prevention Trial, which included approximately 18,000 men aged 55-70 years, investigated the effects of finasteride (Proscar) on prostate cancer risk. The study found an overall reduction in prostate cancer risk of about 25% when considering all biopsies and about 10% for "for cause" biopsies. After adjusting for the decrease in prostate size due to finasteride, the analysis by Kaplan et al. identified a reduction of about 50% for Gleason score 6 cancer and 20% for Gleason score 7 cancer. These findings suggested a significant impact of finasteride on reducing prostate cancer risk.
124 citations
,
January 1993 in “The Prostate” Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.
73 citations
,
January 1994 in “European Urology” Finasteride works better than Permixon in reducing dihydrotestosterone levels.
43 citations
,
January 2007 in “Gynecological Endocrinology” Finasteride improves acne and hair loss in women with normal testosterone.
26 citations
,
July 1995 in “Neurobiology of Aging” Finasteride affects prostate weights and pituitary activity differently with age.
23 citations
,
June 1999 in “Clinical Therapeutics” Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.
11 citations
,
October 1994 in “The Journal of Clinical Endocrinology and Metabolism” Finasteride increases hair growth, prolongs hair cycle, and lowers dihydrotestosterone levels.
